Your browser doesn't support javascript.
loading
Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing.
Sibandze, Doctor B; Kay, Alexander; Dreyer, Viola; Sikhondze, Welile; Dlamini, Qiniso; DiNardo, Andrew; Mtetwa, Godwin; Lukhele, Bhekumusa; Vambe, Debrah; Lange, Christoph; Glenn Dlamini, Muyalo; Ness, Tara; Mejia, Rojelio; Kalsdorf, Barbara; Heyckendorf, Jan; Kuhns, Martin; Maurer, Florian P; Dlamini, Sindisiwe; Maphalala, Gugu; Niemann, Stefan; Mandalakas, Anna.
Afiliação
  • Sibandze DB; National Tuberculosis Reference Laboratory, Eswatini National Health Services Laboratory, Ministry of Health, Mbabane, Eswatini.
  • Kay A; Baylor College of Medicine Children's Foundation-Eswatini, Mbabane, Eswatini.
  • Dreyer V; Global Tuberculosis Program, Baylor College of Medicine, Houston, TX, USA.
  • Sikhondze W; Department of Global Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Dlamini Q; Baylor College of Medicine Children's Foundation-Eswatini, Mbabane, Eswatini. Alexander.kay@bcm.edu.
  • DiNardo A; Global Tuberculosis Program, Baylor College of Medicine, Houston, TX, USA. Alexander.kay@bcm.edu.
  • Mtetwa G; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
  • Lukhele B; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
  • Vambe D; Department of Global Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Lange C; Eswatini National Tuberculosis Program, Ministry of Health, Mbabane, Eswatini.
  • Glenn Dlamini M; Baylor College of Medicine Children's Foundation-Eswatini, Mbabane, Eswatini.
  • Ness T; Global Tuberculosis Program, Baylor College of Medicine, Houston, TX, USA.
  • Mejia R; Global Tuberculosis Program, Baylor College of Medicine, Houston, TX, USA.
  • Kalsdorf B; Baylor College of Medicine Children's Foundation-Eswatini, Mbabane, Eswatini.
  • Heyckendorf J; Global Tuberculosis Program, Baylor College of Medicine, Houston, TX, USA.
  • Kuhns M; Baylor College of Medicine Children's Foundation-Eswatini, Mbabane, Eswatini.
  • Maurer FP; Global Tuberculosis Program, Baylor College of Medicine, Houston, TX, USA.
  • Dlamini S; Eswatini National Tuberculosis Program, Ministry of Health, Mbabane, Eswatini.
  • Maphalala G; Global Tuberculosis Program, Baylor College of Medicine, Houston, TX, USA.
  • Niemann S; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
  • Mandalakas A; Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Genome Med ; 14(1): 52, 2022 05 19.
Article em En | MEDLINE | ID: mdl-35585607
ABSTRACT

BACKGROUND:

Stool is an important diagnostic specimen for tuberculosis in populations who struggle to provide sputum, such as children or people living with HIV. However, the culture of Mycobacterium tuberculosis (M. tuberculosis) complex strains from stool perform poorly. This limits the opportunity for phenotypic drug resistance testing with this specimen. Therefore, reliable molecular methods are urgently needed for comprehensive drug resistance testing on stool specimens.

METHODS:

We evaluated the performance of targeted next-generation sequencing (tNGS, Deeplex® Myc-TB) for the detection of mutations associated with M. tuberculosis complex drug resistance on DNA isolated from stool specimens provided by participants from a prospective cohort of patients treated for tuberculosis in Eswatini (n = 66; 56 with and 10 participants without M. tuberculosis complex DNA detected in stool by real-time quantitative PCR), and an independent German validation cohort of participants with culture-confirmed tuberculosis (n = 21).

RESULTS:

The tNGS assay detected M. tuberculosis complex DNA in 38 of 56 (68%) samples; for 28 of 38 (74%) samples, a full M. tuberculosis complex drug resistance prediction report was obtained. There was a high degree of concordance with sputum phenotypic drug susceptibility results (κ = 0.82). The ability to predict resistance was concentration-dependent and successful in 7/10 (70%), 18/25 (72%), and 3/21 (14%) of samples with stool PCR concentration thresholds of > 100 femtogram per microliter (fg/µl), 1 to 100 fg/µl, and < 1 fg/µl, respectively (p = 0.0004). The German cohort confirmed these results and demonstrated a similarly high concordance between stool tNGS and sputum phenotypic drug susceptibility results (κ = 0.84).

CONCLUSIONS:

tNGS can identify drug resistance from stool provided by tuberculosis patients. This affords the opportunity to obtain critical diagnostic information for tuberculosis patients who struggle to provide respiratory specimens.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Mycobacterium tuberculosis Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Mycobacterium tuberculosis Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article